Assembly Biosciences Reports 58% Increase in Collaboration Revenue for Q3 2025

Assembly Biosciences, Inc. reported its financial results for the third quarter of 2025, revealing a collaboration revenue of $10.8 million, a 58% increase from $6.8 million in the same period last year. For the nine months ending September 30, 2025, collaboration revenue reached $29.8 million, up 41% from $21.2 million in 2024. The increase in revenue is attributed to higher costs incurred under the Gilead Collaboration Agreement, which has been a significant source of funding for the company.

The company's operating expenses for the third quarter totaled $21.7 million, compared to $17.8 million in the prior year, marking a 22% increase. This rise was primarily driven by increased research and development costs, which amounted to $16.6 million, up from $13.5 million in the same quarter of 2024. The increase in R&D expenses reflects the advancement of clinical programs, particularly for the company's investigational therapies targeting herpes simplex virus and hepatitis B virus. General and administrative expenses also rose to $5.1 million from $4.3 million, largely due to higher professional fees and stock-based compensation.

As of September 30, 2025, Assembly Biosciences reported total assets of $240.0 million, significantly up from $119.2 million at the end of 2024. The increase in assets is largely due to a substantial rise in marketable securities, which grew to $210.0 million from $73.7 million. The company’s cash and cash equivalents decreased to $22.5 million from $38.3 million, reflecting ongoing operational expenditures. The total liabilities decreased to $57.3 million from $85.8 million, primarily due to a reduction in deferred revenue from related parties.

In terms of strategic developments, Assembly Biosciences completed a significant financing round in August 2025, raising approximately $175 million through the sale of common stock and warrants. This financing included a private placement with Gilead, which contributed $45 million. The company has also made progress in its clinical pipeline, with multiple Phase 1 studies underway for its antiviral candidates, including ABI-5366 and ABI-1179, both targeting recurrent genital herpes. The company anticipates moving into Phase 2 studies for these candidates in the near future.

Looking ahead, Assembly Biosciences expects to continue incurring losses as it advances its clinical programs and seeks regulatory approvals. The company believes it has sufficient capital to fund its operations into late 2027, not accounting for potential future payments from Gilead or additional financing. The ongoing collaboration with Gilead is expected to provide further financial support and may enhance the company's ability to bring its innovative therapies to market.